VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801

Tsukasaki, Kunihiro; Utsunomiya, Atae; Fukuda, Haruhiko; Shibata, Taro; Fukushima, Takuya; Takatsuka, Y; Ikeda, Shu‐ichi; Masuda, Masato; Nagoshi, H; Ueda, Ryuzo; Tamura, Kazuo; Sano, Masayuki; Momita, Saburo; Yamaguchi, Kazunari; Kawano, Fumio; Hanada, Shuichi; Tobinai, Kensei; Shimoyama, M; Hotta, Tomomitsu; Tomonaga, Masao

doi:10.1200/jco.2007.11.9958

Public

VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801

Published in Journal of Clinical Oncology • Oct 29, 2007

Authors:

Kunihiro Tsukasaki

Atae Utsunomiya

Haruhiko Fukuda

Abstract

PURPOSE: Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma (ATLL) with vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP), doxorubicin, ranimustine, and prednisone (AMP), and vindesine, etoposide, carboplatin, and pred...

Subject

Medicine

Vincristine

Prednisone

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!